Under construction – not a live service
Sign in
TerminatedNo phase

Study of Probable Benefit of the Neuro-Spinal Scaffold™ in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care

Key facts

Who runs it
InVivo Therapeutics
Where
Baltimore, Colorado Springs, Elmhurst, Greenville, Iowa City, Milwaukee, New York, Newark, Philadelphia, Pittsburgh, Providence, Sacramento, San Antonio, San Diego, and Tampa, United StatesSee the 16 sites
Trial code
Status
Terminated
People taking part
20 people enrolled
Started
21 May 2019
Ended
31 Dec 2023
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Neuro-Spinal Scaffold
Record updated
17 January 2024
Why it stopped
Primary Endpoint not met

Who can take part

Age
16 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • AIS A classification of traumatic spinal cord injury at T2 - T12 neurological level of injury confirmed by a qualified medical professional
  • Recent injury (must have open spine surgery within 7 days from injury)
  • Injury Severity Score (ISS) ≤ 45 at the time of screening
  • Glasgow Coma Scale, GCS ≥ 14 (GCS ≥ 10 for intubated subjects) at the time of the screening and GCS = 15 (GCS ≥ 10 for intubated subjects) within two hours prior to spine surgery
  • Non-penetrating SCI (contusion injury) that is no less than approximately 4 mm in diameter by MRI
  • Requires open spine surgery allowing access to the injured spinal cord (subjects requiring either posterior surgical approach or posterior plus anterior approach will be eligible)
  • Informed consent obtained
  • 16-70 years of age, inclusive
  • Eight-hour period of hemodynamically stability (>90 mmHg systolic blood pressure) prior to open spine surgery

Who cannot take part

  • Subjects with clinically significant pre-existing neurological comorbidities that are unrelated to the contusion being treated (e.g. MS, ALS, significant prior peripheral nerve dysfunction, residual problems related to previous spine-related neurological pathologies) will be excluded only if it is felt that these preexisting morbidities will increase risk, affect safety monitoring, or confound study results
  • A female who is:; Pregnant, or planning to become pregnant within the next 12-months; or; Breastfeeding; or; A woman of child-bearing potential (defined as post menarche and biologically capable of becoming pregnant [i.e., not surgically sterile]) who is engaged in active heterosexual relations and is not willing to use a barrier or hormonal form of birth control for 12-months following open spine surgery (e.g., oral, injected, or implanted contraceptives)
  • A male who is engaged in active heterosexual relations and is not willing to use birth control for 3-months following open spine surgery including sperm donation or banking
  • Participation in another interventional clinical trial for six months after open spine surgery
  • Having a medical condition (e.g., cardiovascular disease, life threatening injuries), or receiving medical treatment, or having any other reason that, in the judgment of the Investigator, precludes successful participation and follow-up for at least six months or confounds collection or interpretation of study safety, feasibility, or efficacy data
  • Subjects receiving tetracyclines, such as minocycline (subjects must discontinue tetracyclines to be enrolled in the study; tetracyclines can be resumed after 6 months post-open spine surgery
  • Subjects with clinically significant pre-existing respiratory disease not related to the contusion being treated (e.g., COPD)
  • Subjects with documented immune deficiency disorders, including a known diagnosis of HIV infection/AIDS
  • Recent (according to DSM IV or DSM V criteria) history of abuse of narcotics or other significant substance abuse
  • Known hypersensitivity to PLGA or PLL (e.g., hypersensitivity to absorbable sutures containing PLGA)
  • History of severe mental illness (according to DSM IV or V)
  • Evidence of pre-trauma active local or systemic infection
  • Terminally ill subjects not likely to be able to participate in follow-up
  • Incomplete spinal cord injury (AIS B, C, D, and E injuries)
  • Subjects with more than one discrete spinal cord injury
  • No discrete cavity in the contused spinal cord in which a Scaffold can be placed
  • Evidence of clear and significant Somatosensory Evoked Potentials (SSEP) transmission through the injury site (based on the judgment of the Investigator)
  • Spinal cord injury associated with significant traumatic brain injury or coma that, in the opinion of the Investigator, would preclude adequate assessment of spinal cord function, brain injury that could be associated on its own with sensory or motor deficits, or subjects with any other reason that results in an unreliable ISNCSCI exam
  • Subjects requiring long-term ongoing mechanical ventilation
  • Significant injury complications where, in the view of the Investigator, participation in the study could further complicate subject care, limit study follow-up, or confound interpretation of safety or efficacy data
  • Current or impending incarceration
  • Complete spinal cord transection as determined by screening MRI
  • Subjects with spinal cord injuries directly due to gunshot, knife, or other penetrating wounds
  • BMI over 39

Where in United States

  • University of Maryland Medical CenterBaltimore, United StatesNo longer taking part
  • University of Colorado Memorial Hospital CentralColorado Springs, United StatesNo longer taking part
  • Elmhurst Hospital CenterElmhurst, United StatesNo longer taking part
  • Vidant Medical CenterGreenville, United StatesNo longer taking part
  • University of IowaIowa City, United StatesNo longer taking part
  • Medical College of WisconsinMilwaukee, United StatesNo longer taking part
  • Icahn School of Medicine at Mount SinaiNew York, United StatesNo longer taking part
  • Rutgers Center for Spine SurgeryNewark, United StatesNo longer taking part
  • Penn Presbyterian Medical CenterPhiladelphia, United StatesNo longer taking part
  • Thomas Jefferson UniversityPhiladelphia, United StatesNo longer taking part
  • University of Pittsburgh Medical Center PresbyterianPittsburgh, United StatesNo longer taking part
  • Rhode Island HospitalProvidence, United StatesNo longer taking part
  • UC Davis Medical CenterSacramento, United StatesNo longer taking part
  • University of Texas Health - San AntonioSan Antonio, United StatesNo longer taking part
  • University of California San DiegoSan Diego, United StatesNo longer taking part
  • University of South Florida Health NeurosurgeryTampa, United StatesNo longer taking part

About the trial

What the trial wants to find out

This is a randomized, controlled, single-blind, multicenter, two Arm (Treatment or "Scaffold" Arm; Standard of Care or "Comparator" Arm) of a Neuro-Spinal Scaffold to evaluate whether the Scaffold is safe and demonstrates probable benefit for the treatment of complete T2-T12 spinal cord injury as compared to standard of care open spine surgery.

The 2 groups in the trial

  • Neuro-Spinal Scaffold ArmTreatment being tested

    Subjects in the Scaffold Arm will have the Scaffold implantation immediately following standard of care open spine surgery.

    Treatment: Neuro-Spinal Scaffold

  • Comparator ArmNo study treatment, for comparison

    Subjects in the Comparator Arm will have standard of care open spine surgery and will not receive the Scaffold.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Randomized, Controlled, Single-blind Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects With Complete Thoracic AIS A Spinal Cord Injury as Compared to Standard of Care
Record updated
17 January 2024